Candida nivariensis: Identification strategy in mycological laboratories

Cartier, Nathalie; Chesnay, Adélaïde; Ndiaye, D.; Thorey, C.; Ferreira, Maciel Horácio; Haillot, O.; Bailly, Éric; Désoubeaux, Guillaume

doi:10.1016/j.mycmed.2020.101042

Cited by 9 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The special isavuconazole MIC obtained in this case from UT Health San Antonio of 0.125 µg/mL is similar to and falls within the MIC range of 0.015-0.25 µg/mL for the C. nivariensis isolates from vaginal and bronchial specimens reported in Sharma et al [7]. An elevated fluconazole MIC of 4 µg/mL with lower MICs to other triazoles, like itraconazole and isavuconazole, is similar to susceptibility patterns seen in other case reports [1][2][3]. MIC interpretations are not available as no established breakpoints for C.…”

Section: Discussionsupporting

confidence: 86%

“…C. nivariensis is identified through the use of genotypic measures such as multiplex polymerase chain reaction (PCR) or matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry which most accurately distinguishes it from other members of the C. glabrata complex (e.g., C. glabrata and Candida bracarensis) [1][2][3]. In a review of previous reports containing 130 isolates of C. nivariensis, the fluconazole minimum inhibitory concentration (MIC) varied widely from 0.06 µg/mL to >256 µg/mL [1]. Similar to C. glabrata, C. nivariensis is often resistant or susceptible-dose dependent to fluconazole [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

“…In a review of previous reports containing 130 isolates of C. nivariensis, the fluconazole minimum inhibitory concentration (MIC) varied widely from 0.06 µg/mL to >256 µg/mL [1]. Similar to C. glabrata, C. nivariensis is often resistant or susceptible-dose dependent to fluconazole [1][2][3]. Sources of isolated C. nivariensis include blood, vaginal secretions, urine, oropharyngeal secretions, cerebrospinal fluid, ascitic fluid, nails, and bronchial-alveolar lavage (BAL) fluid [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

“…Similar to C. glabrata, C. nivariensis is often resistant or susceptible-dose dependent to fluconazole [1][2][3]. Sources of isolated C. nivariensis include blood, vaginal secretions, urine, oropharyngeal secretions, cerebrospinal fluid, ascitic fluid, nails, and bronchial-alveolar lavage (BAL) fluid [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of Candida nivariensis Blood Stream Infection With Oral Isavuconazole

Randazza¹,

Erickson²,

Denmeade³

et al. 2022

Cureus

View full text Add to dashboard Cite

Candida nivariensis is a rarely isolated yeast that is now considered a species within the Candida glabrata complex. Anti-fungal susceptibilities and treatments of Candida nivariensis are often assessed on a case-bycase basis. In this case, a 70-year-old male with a complex medical history presented to a large academic medical center in the United States for vascular surgery. After surgery, the patient's white blood cell count increased prompting an infectious workup. The patient was found to have a Candida nivariensis bloodstream infection of unknown origin. Given the patient's clinical stability and QTc prolongation, he was treated with a 14-day course of oral isavuconazole. The patient experienced resolution of symptoms and clearance of subsequent blood cultures. At the time of writing this case report (11 months later), he has had no relapse of his fungal infection. Based on a search of the medical literature, this appears to be the first published case of Candida nivariensis fungemia successfully treated with oral isavuconazole.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Candida nivariensis Blood Stream Infection With Oral Isavuconazole

Randazza¹,

Erickson²,

Denmeade³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Several reports used ITS-based PCRs to rapidly identify Candida spp. at the species level, including intrinsically resistant (e.g., C. krusei /FLC) [ 34 ] and less susceptible cryptic species [ 35 , 36 , 37 , 38 ]. Similarly, for Mucorales, ITS alone is a correct DNA marker with enough discriminative power to identify the currently accepted morphospecies of Mucor , Lichtheimia, and Rhizopus [ 39 , 40 ].…”

Section: Intrinsic Resistance Detectionmentioning

confidence: 99%

Molecular Markers of Antifungal Resistance: Potential Uses in Routine Practice and Future Perspectives

García‐Effrón

2021

JoF

View full text Add to dashboard Cite

Antifungal susceptibility testing (AST) has come to establish itself as a mandatory routine in clinical practice. At the same time, the mycological diagnosis seems to have headed in the direction of non-culture-based methodologies. The downside of these developments is that the strains that cause these infections are not able to be studied for their sensitivity to antifungals. Therefore, at present, the mycological diagnosis is correctly based on laboratory evidence, but the antifungal treatment is undergoing a growing tendency to revert back to being empirical, as it was in the last century. One of the explored options to circumvent these problems is to couple non-cultured based diagnostics with molecular-based detection of intrinsically resistant organisms and the identification of molecular mechanisms of resistance (secondary resistance). The aim of this work is to review the available molecular tools for antifungal resistance detection, their limitations, and their advantages. A comprehensive description of commercially available and in-house methods is included. In addition, gaps in the development of these molecular technologies are discussed.

show abstract